Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Duster340 on Jan 19, 2024 3:52pm

also 🚩

i think a lot of those newly issued shares are not even tradeable yet. but they will be next week
Comment by Montana5 on Jan 19, 2024 4:34pm
So you exercise your warrants at a dollar and then try to sell them for a loss?? Doesn't make sense. The selling we are seeing now is due to frustration more than anything else. The dilutive effect is irrelevant as it is really about the success of Otena vs the survival of this company.
Comment by MrMugsy on Jan 20, 2024 12:08pm
Agree Montana5. The only thing I'd add for thought/discussion is ... I've been watching the stock for a long time now and it doesn't take much for people to swing the share price. There really aren't many trading here and its the same old crew who've been here, left and come back.  Very few new holders - it seems. I personally won't even entertain the price/value ...more  
Comment by Montana5 on Jan 21, 2024 7:53pm
A successful P2 for acute will likely move the share price to at least $2.50 for ATE to consider another equity issue. It would help self fund P3 and other potential developments (clinically and corporate).
Comment by Benedictus on Jan 25, 2024 10:53pm
While the Jan 18 update was timely and informative, if mgt was relying on this alone to strengthen the sp and allow the discounted warrant exercise funds to flow in, they appear to have seriously miscalculated the market.The arbitration was not even mentioned and so it remains a risk and without announcing a positive resolution, it seems very unlikely any warrant holders would exercise even if $1 ...more  
Comment by MrMugsy on Jan 28, 2024 8:58am
Benedictus - from AGM, we know there is confidence on a few fronts.  We also know there are discussions underway.  No details, just that the company is doing what they can in advance. and ... with a mountain of OTENA data behind us, we know where we stand with amorphous.  In God's hands now w.r.t. financing. I wouldn't read much into the last presentation or any ...more  
Comment by Benedictus on Jan 30, 2024 12:46am
Thanks Mugs, appreciate your perspective as always. Should be an exciting year!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities